NCT07248280
Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients
레지스트리 요약
- 진행 상태
- 완료 (COMPLETED)
- 질환/조건
- Nausea and Vomiting, Postoperative, Prevention
- 시험 유형
- 중재 연구 (INTERVENTIONAL)
- 단계
- Phase 3
- 목적
- 예방
- 중재 유형
- 약물
- 개입·치료
- Aprepitant 40mg, Placebo
- Lead Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM) (기타)
캐시 시각: 2026-08-28 23:27:21
요약
Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis.
Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited.
This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.
Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited.
This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.
카카오 로그인 후 의뢰